In pursuit of its growth strategy for the BIOSOLUTIONS life-science division, WACKER is ramping up capacities in the biopharmaceutical realm, particularly for advanced therapies. Wacker Biotech US, a subsidiary specializing in fermentative production of plasmid DNA (pDNA), is broadening its…
GC Biopharma Presents New Data at CIS 2026 to Expand Analytical Understanding of IVIG Product Characteristics GC Biopharma USA, Inc., a leader in plasma-derived products, announced the presentation of new data at the 2026 Clinical Immunology Society (CIS) Annual Meeting…
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource…
Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB Two River, LLC and Vida Ventures both part of the Bellco Health ecosystem, acknowledged the announced acquisition of Candid…
UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers UCB, a global biopharmaceutical company, announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company…
Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC) Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients…
Valo Health Appoints Chris Anagnostopoulos, PhD, as Chief Causal AI Officer Valo Health, Inc. a pioneer in the use of human data and AI to accelerate drug discovery and development, announced the appointment of Chris Anagnostopoulos, PhD, C.Stat, to the…
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS Travere Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients…
ADDING MULTIMEDIA Byondis Appoints Christoph Korpus, PhD, MBA as Chief Executive Officer Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces today the appointment of Christoph Korpus, PhD, MBA, as Chief Executive Officer (CEO), effective…
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director Coya Therapeutics, Inc. a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that founder Howard Berman,…
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right Aurinia Pharmaceuticals Inc. a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced…
LIB Therapeutics Announces Results from Presentations on LEROCHOL® at 2026 American College of Cardiology meeting in New Orleans March 28-29, 2026 LIB Therapeutics Inc. a privately-held, biopharmaceutical company with a recently approved novel, monthly, small dose third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga), announced…